Work

495P Safety and efficacy of nab-sirolimus (HB1901) + endocrine therapy in HR+/HER2- advanced breast cancer after standard therapy failure: A multicenter, open-label, phase 2 study

Year: 2025

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.918

Authors: F. Ma, Q. Zhang, H. Mo, J. Cui, B. Zhao, F. Xu, L. Wang, G. Lu, Y. Liu, F. Luo, Z. Song, Y. Lv, X. Wang, T. Sun, X. Ling, H. Sun, Y. Yin, C. Wang, C. Xia, Y. Xin

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Third Affiliated Hospital of Harbin Medical University, First Hospital of Jilin University, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, Sun Yat-sen University Cancer Center, Xingtai People's Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University, Xuzhou Central Hospital, Shanxi Provincial Cancer Hospital, Fourth Hospital of Hebei Medical University, Ningxia Medical University, Ningxia Medical University General Hospital, Suzhou Municipal Hospital, Liaoning Cancer Hospital & Institute, First Hospital of Lanzhou University, Lanzhou University, Jiangsu Province Hospital, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical University, CSPC Pharmaceutical Group

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415942552

FWCI: 0.661

Cites:

Cited by: 1

Related to: 10